TY - JOUR
T1 - Isolation and preliminary characterization of an adriamycin-resistant murine fibrosarcoma cell line
AU - Giavazzi, R.
AU - Scholar, E.
AU - Hart, I. R.
PY - 1983
Y1 - 1983
N2 - A variant cell line (UV-2237-ADM(R)) resistant to the anthracycline antibiotic Adriamycin (doxorubicin) was selected in vitro from the murine UV-2237 fibrosarcoma tumor cell line. Resistance to Adriamycin proved to be a stable characteristic of the UV-2237-ADM(R) line, whether the line was grown in vivo or in vitro. The UV-2237-ADM(R) line also exhibited increased resistance to N-trifluoroacetyladriamycin-14-valerate, daunorubicin, actinomycin D, amsacrine, mitomycin C, vinblastine, and vincristine but not to bleomycin. Cell-cell hybridization studies showed that the Adriamycin resistance is an incompletely dominant trait. Uptake and efflux studies with [14C]Adriamycin indicated that the resistance exhibited by the UV-2237-ADM(R) line was due to both reduced uptake of the drug and an increased active efflux.
AB - A variant cell line (UV-2237-ADM(R)) resistant to the anthracycline antibiotic Adriamycin (doxorubicin) was selected in vitro from the murine UV-2237 fibrosarcoma tumor cell line. Resistance to Adriamycin proved to be a stable characteristic of the UV-2237-ADM(R) line, whether the line was grown in vivo or in vitro. The UV-2237-ADM(R) line also exhibited increased resistance to N-trifluoroacetyladriamycin-14-valerate, daunorubicin, actinomycin D, amsacrine, mitomycin C, vinblastine, and vincristine but not to bleomycin. Cell-cell hybridization studies showed that the Adriamycin resistance is an incompletely dominant trait. Uptake and efflux studies with [14C]Adriamycin indicated that the resistance exhibited by the UV-2237-ADM(R) line was due to both reduced uptake of the drug and an increased active efflux.
UR - http://www.scopus.com/inward/record.url?scp=0020527683&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020527683&partnerID=8YFLogxK
M3 - Article
C2 - 6831444
AN - SCOPUS:0020527683
SN - 0008-5472
VL - 43
SP - 2216
EP - 2222
JO - Journal of Cancer Research
JF - Journal of Cancer Research
IS - 5
ER -